A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters

Georgianna G Gould, Alfonso V. Altamirano, Martin A Javors, Alan Frazer

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesizebd that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Methods: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Results: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Conclusions: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.

Original languageEnglish (US)
Pages (from-to)408-414
Number of pages7
JournalBiological Psychiatry
Volume59
Issue number5
DOIs
StatePublished - Mar 1 2006

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Serotonin Plasma Membrane Transport Proteins
Antidepressive Agents
Binding Sites
Desipramine
Sertraline
Paroxetine
Amitriptyline
Venlafaxine Hydrochloride
Oxidopamine
Serotonin Uptake Inhibitors
Autoradiography
Norepinephrine

Keywords

  • Amitriptyline
  • Dual uptake inhibitor
  • Norepinephrine transporter
  • Quantitative autoradiography
  • Serotonin transporter
  • Venlafaxine

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. / Gould, Georgianna G; Altamirano, Alfonso V.; Javors, Martin A; Frazer, Alan.

In: Biological Psychiatry, Vol. 59, No. 5, 01.03.2006, p. 408-414.

Research output: Contribution to journalArticle

@article{9169c8052ece4012a1b0090c94694ad5,
title = "A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters",
abstract = "Background: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesizebd that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Methods: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Results: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Conclusions: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.",
keywords = "Amitriptyline, Dual uptake inhibitor, Norepinephrine transporter, Quantitative autoradiography, Serotonin transporter, Venlafaxine",
author = "Gould, {Georgianna G} and Altamirano, {Alfonso V.} and Javors, {Martin A} and Alan Frazer",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.biopsych.2005.07.011",
language = "English (US)",
volume = "59",
pages = "408--414",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters

AU - Gould, Georgianna G

AU - Altamirano, Alfonso V.

AU - Javors, Martin A

AU - Frazer, Alan

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesizebd that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Methods: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Results: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Conclusions: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.

AB - Background: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesizebd that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Methods: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Results: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Conclusions: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.

KW - Amitriptyline

KW - Dual uptake inhibitor

KW - Norepinephrine transporter

KW - Quantitative autoradiography

KW - Serotonin transporter

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=33344465355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33344465355&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2005.07.011

DO - 10.1016/j.biopsych.2005.07.011

M3 - Article

C2 - 16140280

AN - SCOPUS:33344465355

VL - 59

SP - 408

EP - 414

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 5

ER -